CareLit · DOI-Nachweis · Diabetologie und Stoffwechsel
Weight loss with once-weekly dulaglutide versus insulin glargine, both with insulin lispro (+/- metformin), in patients with type 2 diabetes (T2D) from AWARD-4, stratified by baseline body mass index (BMI) category
DOI 10.1055/s-0035-1549751
Bibliografische Angaben
Nachweis in CareLit
Autor:innenM Füchtenbusch, E Heitmann, C Nicolay, H Jung
ZeitschriftDiabetologie und Stoffwechsel
Ausgabe04/2015
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Objective: For T2D patients with increased BMI ≥27 kg/m2 or > 35 kg/m2, German national guidelines recommend weight loss of ˜5% or > 10%, respectively. Bodyweight data from the open-label AWARD-4 trial comparing once-weekly dulaglutide 1.5 mg vs. glargine, both with lispro ± metformin, were analysed post hoc by baseline BMI category. Methods: Proportions of patients were described and compared for dulaglutide 1.5 mg…
Zitieren
Zitierempfehlung
M Füchtenbusch, E Heitmann, C Nicolay, H Jung (2015) Weight loss with once-weekly dulaglutide versus insulin glargine, both with insulin lispro (+/- metformin), in patients with type 2 diabetes (T2D) from AWARD-4, stratified by baseline body mass index (BMI) category. Diabetologie und Stoffwechsel (04). https://doi.org/10.1055/s-0035-1549751
Mit CareLit weiterarbeiten